DynaCorts Therapeutics BV of Leidschendam, the Netherlands, is a research-stage biopharmaceutical company. DynaCorts develops innovative and personalized treatments for depression and anxiety disorders.
Our research identified a receptor for the stress hormone cortisol as a new drug target for the treatment of depression and anxiety disorders. This particular cortisol receptor has been named the mineralocorticoid receptor (MR), and is situated in the brain. DynaCorts aims to modulate the MR in depressive patients with a medicine that selectively targets the brain. Optimal treatment is achieved in combination with genotyping the MR for variants of this receptor in stress adaptation and vulnerability to depression.